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Abstract
Cellular immunotherapy has proven to be effective in the treatment of hematological can-
cers by donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation
and more recently by targeted therapy with chimeric antigen or T-cell receptor-engineered T
cells. However, dependent on the tissue distribution of the antigens that are targeted, anti-
tumor responses can be accompanied by undesired side effects. Therefore, detailed tissue
distribution analysis is essential to estimate potential efficacy and toxicity of candidate tar-
gets for immunotherapy of hematological malignancies. We performed microarray gene
expression analysis of hematological malignancies of different origins, healthy hematopoi-
etic cells and various non-hematopoietic cell types from organs that are often targeted in
detrimental immune responses after allogeneic stem cell transplantation leading to graft-
versus-host disease. Non-hematopoietic cells were also cultured in the presence of IFN-γ
to analyze gene expression under inflammatory circumstances. Gene expression was
investigated by Illumina HT12.0 microarrays and quality control analysis was performed to
confirm the cell-type origin and exclude contamination of non-hematopoietic cell samples
with peripheral blood cells. Microarray data were validated by quantitative RT-PCR showing
strong correlations between both platforms. Detailed gene expression profiles were
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generated for various minor histocompatibility antigens and B-cell surface antigens to illus-
trate the value of the microarray dataset to estimate efficacy and toxicity of candidate tar-
gets for immunotherapy. In conclusion, our microarray database provides a relevant
platform to analyze and select candidate antigens with hematopoietic (lineage)-restricted
expression as potential targets for immunotherapy of hematological cancers.
Introduction
Cellular immunotherapy of hematological cancers has proven very effective. After allogeneic
hematopoietic stem cell transplantation (alloSCT), anti-tumor immunity is mediated by donor
T cells recognizing the malignant cells of the patient [1]. Another effective approach is targeted
therapy by chimeric antigen receptor (CAR) or T-cell receptor (TCR) gene transfer. CAR T-
cell therapy specific for CD19 has successfully been used to treat patients with B-cell malignan-
cies [2]. In addition to strong anti-tumor immunity, immunotherapy can cause life-threatening
toxicity, i.e. liver or neurological damage as reported after CAR or TCR gene therapy [3, 4] or
graft-versus-host disease (GvHD) after alloSCT [5], due to on-target recognition of healthy
organs by the adoptively transferred T cells. Both the efficacy and potential toxicity of immu-
notherapy is strongly dependent on the tissue distribution of the antigens that are targeted.
Thus, gene expression profiles of candidate targets for immunotherapy of hematological can-
cers need to be carefully examined.
Immunotherapy can be directed against extracellular or intracellular antigens. Specific anti-
bodies or CARs can recognize extracellular antigens that are expressed on the cell surface of
malignant cells. These antigens need to be selectively expressed on the tumor or on the lineage
from which the tumor originates to limit the risk of toxicity [2, 6]. Intracellular antigens can be
targeted by specific TCRs when peptides from these proteins are presented by HLA on the cell
surface. As such, the repertoire of candidate antigens that can be targeted by TCR-based immu-
notherapy extends beyond extracellular antigens, but the necessity for tumor- or lineage-
restricted expression remains. In the setting of alloSCT, polymorphic antigens with hematopoi-
etic-restricted expression are relevant targets for immunotherapy, since donor T cells recogniz-
ing these antigens eliminate the malignant cells of the patient, while sparing healthy
hematopoietic cells of donor origin. Polymorphic peptides that are targeted by donor T cells
after HLA-matched alloSCT, so-called minor histocompatibility antigens, can be efficiently
discovered by whole genome association scanning and minor histocompatibility antigens with
hematopoiesis-restricted expression are selected as targets with potential therapeutic relevance
[7–11]. Ideally, the tissue distribution of minor histocompatibility antigens is analyzed by mea-
suring T-cell recognition of a large variety of (malignant) hematopoietic and non-hematopoi-
etic cell types cultured from tissues that are targeted in GvHD. However, non-hematopoietic
cells are often difficult to culture and not available in quantities that allow in depth T-cell anal-
ysis. Therefore, as an alternative, the tissue distribution can be estimated by determining gene
expression.
Whole transcriptome analysis can be performed by microarray gene expression or RNA-
sequence analysis. Microarray data have become increasingly available over the years in plat-
forms such as Gene Expression Omnibus [12, 13]. However, integration of datasets is challeng-
ing due to differences in sample handling and technologies. Various integrated and normalized
datasets are offered now and allow online analysis of tissue expression. Oncomine is a large
platform providing cancer microarray data [14], while BioGPS, among others, allows easy
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access to Gene Atlas datasets [15]. GeneSapiens [16] provides a bioinformatic analysis of
~10,000 samples including normal human tissues, different cancer types and cell lines. Many
samples in these databases represent whole tissues, which are composed of a mix of non-
hematopoietic cell types that are often contaminated with peripheral blood cells. Gene expres-
sion profiles from these samples are heterogeneous in nature and do not allow accurate identi-
fication of hematopoiesis (lineage)-restricted genes. The value of existing datasets with whole
tissue samples for estimating the therapeutic relevance and potential toxicity of candidate tar-
gets for immunotherapy of hematological malignancies thus remains limited.
AlloSCT and CAR/TCR gene transfer are treatments that can induce inflammation in
patients in particular upon development of an effective anti-tumor response [17–19]. There-
fore, to estimate potential toxicity, expression of the antigen targeted by immunotherapy needs
to be investigated under inflammatory conditions. However, whole tissues or non-hematopoi-
etic cells are generally collected for transcriptome analysis under non-inflammatory conditions
and on line databases are therefore of limited use to estimate potential toxicity of immunother-
apeutic targets.
In this study, we performed microarray gene expression analysis on hematological malig-
nancies of different origins isolated from bone marrow or peripheral blood based on expression
of specific surface markers. We also collected healthy hematopoietic cells and non-hematopoi-
etic cells from organs that are often targeted in GvHD. Non-hematopoietic cells were cultured
from tissue specimen or biopsies and various non-hematopoietic cell types were cultured in the
presence of IFN-γ to mimic inflammation. Gene expression was investigated by Illumina
HT12.0 microarray and quality control analysis confirmed the cell-type origin of the samples
and excluded contamination of non-hematopoietic cell samples with peripheral blood cells.
We validated gene expression as measured by microarray gene expression analysis by quantita-
tive RT-PCR and investigated gene expression in non-hematopoietic cells under conditions of
inflammation. Finally, we illustrated the value of our dataset to estimate efficacy and toxicity of
potential targets for immunotherapy of hematological malignancies.
Materials and Methods
Collection of human samples
Malignant and normal hematopoietic cells were isolated from peripheral blood or bone marrow
samples and non-hematopoietic cell types were obtained from tissue biopsies or surgically
removed specimen obtained from patients or healthy individuals after approval by the Medical
Research Ethics Committee and Institutional Review Board of the Leiden University Medical
Center (LUMC) and informed consent according to the Declaration of Helsinki. The majority of
samples were collected after 2002 and written informed consent was obtained for these samples.
Only for leukemic samples collected before 2002, oral informed consent was documented in the
patient files by the patient’s physician as the only procedure approved by the ethical board.
Isolation and culture of healthy hematopoietic cells
Detailed isolation and culture methods are described in S1 Methods. Briefly, bone marrow and
peripheral blood mononuclear cells (BMMC and PBMC) were isolated by Ficoll-Isopaque sep-
aration and cryopreserved. B cells, T cells, monocytes and hematopoietic stem cells were puri-
fied by fluorescence-activated cell sorting. Immature DC (imDC) were generated from isolated
monocytes and further differentiated into mature DC (matDC). Isolated monocytes were also
used to generate M1 and M2 macrophages (MФ). EBV-transformed B-cell lines (EBV-LCL)
and PHA-stimulated T-cell lines (PHA-T) were generated from PBMC as previously described
[20, 21].
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Isolation and characterization of malignant hematopoietic cells
Detailed isolation methods are described in S1 Methods. In short, flow cytometric analyses were
performed on malignant cells, followed by cell sorting based on surface expression of specific
markers. Malignant hematopoietic cells included are acute B-lymphoblastic leukemia (ALL)
cells, chronic lymphocytic leukemia (CLL) cells, CD34-positive chronic myeloid leukemia
(CML) cells, multiple myeloma (MM) cells and acute myeloid leukemia (AML) cells. AML sam-
ples were sorted as single cell populations using antibodies for CD33 or as two separate cell popu-
lations expressing CD33 in the absence or presence of CD14 to distinguish cells differentiated
into the monocytic pathway (CD14pos) frommore immature cells (CD14neg). To classify the
different malignant samples according to WHO 2008 standards [22], FISH and karyotyping was
performed on freshly isolated or cryopreserved cells. For AML samples, additional analyses were
performed to determineNPM1mutations and FLT3 gene internal tandem duplication (FLT3-
ITD) on genomic DNA and CEPBAmutation [23] and EVI1 overexpression [24, 25] on cDNA.
Culture of malignant human cell lines
The human erythroleukemia cell line K562, T-B lymphoblastoid cell line T2, acute myeloid leu-
kemia cell lines AML-193 and THP-1, Burkitt's lymphoma cell line Daudi, acute T cell leuke-
mia cell line Jurkat and the human cervix carcinoma cell line HeLa were obtained from the
ATCC. Burkitt’s lymphoma cell line Raji was kindly provided by M. Ressing (Dept. of Molecu-
lar Cell Biology, LUMC). All cell lines were cultured in IMDM with 10% FCS.
Isolation and culture of non-hematopoietic cells
Fibroblasts, keratinocytes, proximal tubular epithelial cells (PTEC), melanocytes, primary
bronchial epithelial cells (PBEC) and human umbilical vein endothelial cells (HUVEC) were
derived from tissue biopsies or surgically removed specimen from patients or healthy individu-
als at the LUMC. Cornea epithelial (Cornea) and stroma cells were harvested from human
cadaveric eyes obtained from the EuroCorneabank, (Beverwijk, the Netherlands). Hepatocytes
were obtained from Beckton Dickinson (New Jersey, USA) and colon and small intestinal epi-
thelial cells were obtained from epithelial organoid cultures from the Hubrecht Institute for
Developmental Biology and Stem Cell Research (University Medical Centre Utrecht, Utrecht,
The Netherlands). Bile duct epithelial cells were purchased from ScienCell (Carlsbad, CA,
USA). Fibroblasts, keratinocytes, PTEC, melanocytes and HUVEC were also cultured in the
presence of IFN-γ (100 IU/ml) for 4 days to mimic inflammation. In addition, two fibroblast
samples were cultured with T-cell culture supernatant for 4 days. Isolation and culture of pri-
mary cell types from non-hematopoietic tissues was performed as described in S1 Methods.
Total RNA isolation
Total RNA was isolated with normal and micro scale RNAqueous isolation kits (Ambion,
Thermo Fisher Scientific, Waltham, MA, USA) and treated with DNAse I for 30 min at 37°C.
RNA clean-up was performed using RNeasy mini kit (Qiagen, Valencia, CA, USA) and the
quality of isolated RNA was checked using Agilent RNA 6000 Nano and Pico chips and Agilent
Bioanalyzer (Santa Clara, CA, USA). Total RNA was stored at -80°C for gene expression analy-
sis by human HT-12.0 microarrays or quantitative RT-PCR.
Human HT-12.0 microarrays
Total RNA as stored at -80°C was thawed to amplify and biotinylate cRNA using the TotalPrep
RNA amplification kit (Ambion) and T7 Oligo(dT) primer for First Strand cDNA synthesis.
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After preparation, cRNA samples were hybridized onto Human HT-12.0 Version 3 or Version
4 Expression BeadChips (Illumina, San Diego, CA, USA). Hybridization was performed in the
hybridization oven for 17 hours at 58°C. Chips were stained with streptavidin-Cy3 and scanned
using a Bead Array 500 GX scanner. Raw data were imported into Genome Studio (all Illu-
mina) for gene expression quantification. Microarray gene expression data were analyzed with
R 2.15 [26]. For this analysis, all samples as measured on Illumina HT-12 chips versions 3 and
4 were combined and merged in one dataset containing all probes as included on both chip ver-
sions (n = 39,425), of which 28,280 probes (71.7%) are for designated NM transcripts as anno-
tated by RefSeq. Normalization was done in the lumi R package using the variance stabilizing
transformation and quantile normalization [27, 28]. The data discussed in this publication
have been deposited in NCBI's Gene Expression Omnibus [12] and are accessible through
GEO Series accession number GSE76340 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE76340). Probe fluorescence is determined as log-transformed value or as 2 to the
power of the log-transformed value. In comparisons of gene expression profiles between two
sample groups, the average log-transformed values for both groups were subtracted and the
fold increase in probe fluorescence was calculated as 2 to the power of this difference
(2avg1-avg2). Expression profiles could not be determined for all genes that have been described
as (non-)hematopoietic lineage specific markers due to probe absence on the Illumina HT12.0
array or inclusion of probes showing overall non-significant fluorescence.
Quantitative RT-PCR
Total RNA as stored at -80°C was thawed to generate cDNA using M-MLV Reverse Transcrip-
tase and Oligo(dT) primer. Quantitative RT-PCR (q-PCR) was performed using predesigned
Taqman Gene Expression assays (S2 Table) and Universal Master Mix II, no UNG (all Thermo
Fisher Scientific, Waltham, MA, USA) and amplification was measured in real-time using
LightCycler 480 (Roche, Basel, Switzerland). Data were analyzed using LightCycler 480 soft-
ware and fit points analyses. Data was normalized using three reference genes: HMBS (alias:
PBGD), GAPDH and ACTB (alias: β-actin). Amplifications started with 10 minutes at 95°C,
followed by 45 cycles of 30 seconds for denaturing at 95°C, 30 seconds of annealing at 60°C,
and 30 seconds extension at again 60°C. In the regression models, Cp was corrected for a
weighted average of Cp values for the three reference genes.
Statistical methods
The predictability of array expression measurements based on RT-PCR measurements was
investigated. A quadratic prediction model was built for a set of 24 genes. Measurements of ref-
erence genes HMBS, ACTB and GAPDH were available. Missing data was imputed. Data was
measured in two batches and genes are corrected against reference genes measured in the same
batch. For unsupervised clustering analysis, we estimated the sample relation with hierarchical
clustering (average linkage) as provided in the Bioconductor lumi (v2.10.0) R package [28].
Results
Validation of the cell type origin of hematopoietic and non-hematopoietic
samples
Various hematological malignancies of different origins and their healthy non-malignant
counterparts as well as various cell types isolated or cultured from non-hematopoietic tissues
were collected for gene expression profiling by Illumina HT12.0 microarrays to enable high-
throughput analysis and selection of targets with relevant expression profiles for
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immunotherapy of hematological malignancies. The majority of hematopoietic cell types have
been included directly after isolation by flow cytometry based on expression of specific surface
markers. The genes for isolation markers CD19, CD3, CD14 and CD34 showed restricted
expression to B cells, T cells, monocytes and HSC, respectively, thereby confirming the origin
of hematopoietic cell samples (data not shown). All cell types from healthy non-hematopoietic
tissues were included after short-term incubation or culture under specific conditions to elimi-
nate contaminating peripheral blood cells. These cell types were checked and negative for
expression of hematopoietic marker genes, indicating that contamination with peripheral
blood cells was below the detection limit (data not shown). In addition, we generated expres-
sion profiles for various known cell type-associated genes to confirm the origin of non-hemato-
poietic cell samples in our dataset. In Fig 1A, expression of cell type-specific or -associated
genes are shown for hepatocytes, melanocytes, fibroblasts and keratinocytes. Expression pro-
files for cell type-associated genes for PTEC, HUVEC and PBEC (lung) are depicted in S1 Fig.
In addition, profiles for genes that are expressed in the gut are shown as well as profiles for
genes with more specific expression in the small intestine. For bile duct epithelial cells, cell
type-associated genes with significant probe fluorescence could not be identified and cornea
epithelial and cornea stroma cells were shown to share significant gene expression with kerati-
nocytes and fibroblasts, respectively (Fig 1).
For in vitromodified hematopoietic cells, we checked whether the induced cell types prop-
erly differentiated from their original cell type based on expression of a number of pre-defined
genes. DC cultured from monocytes with GM-CSF and IL-4 were checked for down-regulation
of the monocyte-specific CD14 gene and up-regulation of DC-specific genes (Fig 1B, left
panel). Full DC maturation was confirmed by induced gene expression of known maturation
markers and down-regulated expression of markers for immature DC (Fig 1B, right panel).
The combination of these markers allows for quality control and two DC samples were
excluded from the dataset for no or incomplete maturation (Fig 1B). Macrophages (MF) were
generated from isolated monocytes by culturing with GM-CSF (type I MF) or M-CSF (type II
MF). Differentiation to macrophages was confirmed by induced expression ofMMP9 [29] and
SPP1 [30] and expression of CCL2 [31] and CD163 [32] was stronger in type II than in type I
MF (data not shown).
To evaluate the role of inflammation on gene expression in non-hematopoietic cells, we cul-
tured various non-hematopoietic cell types (fibroblasts, keratinocytes, PTEC, melanocytes and
HUVEC) in the presence of IFN-γ. The effect of IFN-γ was checked by measuring expression
of interferon-inducible genes as well as genes involved in HLA-class I and II processing and
presentation (Fig 1C). All samples showed strong up-regulation of these genes after IFN-γ
treatment, except for one HUVEC sample (HUVEC #3), which was excluded from the dataset.
As additional unbiased method for cell type validation, we performed hierarchical clustering
for the complete panel of healthy (non-)hematopoietic samples based on expression profiling
of all genes (S2 Fig). In this analysis, hematopoietic cell types were distinguished from non-
hematopoietic cell types and samples with the same cell type origin clustered based on shared
gene expression profiles. This further validated the cell type origin of the (non-)hematopoietic
cell samples in the microarray dataset and confirmed lack of detectable contamination of non-
hematopoietic cell samples with peripheral blood cells.
Inclusion of hematological malignancies of different origins
All malignant hematopoietic cell types were categorized according to the WHO classification
standards and analyzed for cytogenetic abnormalities and, if applicable, for morphology and
immune phenotype (Table 1 and complex karyotypes in S1 Table). A wide variety of samples
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Fig 1. Validation of the cell type origin of (non-)hematopoietic samples. Probe fluorescence as measured by microarray gene expression
analysis is depicted on the x-axis in logarithmic scale. (A) Gene expression for various cell type-associated genes as determined by microarray
gene expression analysis is shown. Hepatocyte-specific expression is shown for APOA2,ORM1, FGA and ALB and melanocyte-specific
expression is shown forMLANA, SILV, TYRP1 and TYR. Fibroblasts-associated expression as defined by detectable expression in fibroblasts
as well as a limited number of other non-hematopoietic cell types is shown for FBLN2, CD248, ITGA11 and THY1 and keratinocyte-associated
Gene Expression to Analyze Immunotherapeutic Candidates
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were included to obtain a broad repertoire of hematological malignancies. Malignant cell popu-
lations were isolated by flow cytometry based on expression of specific surface markers. Gene
expression for these surface markers is depicted in S3 Fig. In addition to primary hematological
malignancies, we included tumor cell lines K562, T2, AML-193, THP-1, Daudi, Raji, Jurkat
and HeLa.
Validation of microarray gene expression analysis by quantitative
RT-PCR
For all 39,426 probes as included in HT12.0 microarray versions 3 and 4, we determined the
maximum probe fluorescence as measured in any of the 166 (non-)hematopoietic cell samples
in the dataset. Maximum probe fluorescence showed great variability, ranging from log 5.6 to
log 15.2. No or low fluorescence can be the consequence of poor probe quality or absence or
low expression of the gene transcript in the dataset, while high probe fluorescence indicates
that the gene transcript is strongly expressed. To investigate whether gene expression patterns
can be accurately and reliably established with our microarray dataset, we validated microarray
gene expression data by q-PCR for 24 genes that were selected for different maximum probe
fluorescence values.
For 53 samples, which were selected based on wide variability in gene expression through-
out the 24 genes, cDNA was generated from the same mRNA source as used for microarray
gene expression analysis and gene expression was measured by q-PCR. The complete set of
samples, genes, probes and Taqman assays are depicted in S2 and S3 Tables. Using a quadratic
prediction model, the correlation between microarray and q-PCR expression data was deter-
mined by calculating the coefficient of determination (R2). The average correlation for the
entire set of 24 genes was strong (corrected R2 = 0.868). Correlation plots for separate genes are
depicted in S4 Fig. In Table 2, individual R2 values are depicted as well as the maximum probe
fluorescence as measured by microarray gene expression analysis in the sample set for q-PCR
validation. Table 2 shows that R2> 0.67, which indicates that the variability in gene expression
in more than two third of the samples fits between microarray and q-PCR analysis, was mea-
sured for all 11 genes (100%) with a maximum probe fluorescence> log 11, whereas for the
remaining 13 genes with maximum probe fluorescence< log 11, only 3 genes (23%) showed
R2> 0.67.
In conclusion, our data show that gene expression patterns can be accurately established
with our microarray dataset for transcripts with a maximum probe fluorescence> log 11,
while q-PCR analysis is recommended if the transcript of interest has a maximum probe
fluorescence < log 11. If maximum probe fluorescence is< log 11, less detailed qualitative
analysis can still be performed, but quantitative analysis by microarray gene expression is not
possible.
expression is demonstrated for KRT14, LAMA3, KLK5 and DSG3. Fibroblasts, FB; keratinocytes, KC. (B) Gene expression for monocytes and
dendritic cells (DC) is shown (left graph) as well as for immature and mature DC (right graph). Down-regulation of CD14 and up-regulation of
CD86, CD209 andCCL22 is shown for DC (filled bars) cultured frommonocytes (open bars) with GM-CSF and IL-4 (left graph). To validate
maturation of DC, down-regulation of markers for immature DC (CCL13 andCD36) and up-regulation of markers for mature DC (LAMP3,
HLA-DOB, FLT3, CD80, CD83 andHLA-DQA1) was checked (right graph). Immature DC (imDC) are depicted by squares and mature DC
(matDC) are indicated by circles. Red symbols indicate samples which have been excluded from the dataset for incomplete maturation. (C)
Various non-hematopoietic cell types (fibroblasts, keratinocytes, PTEC, melanocytes and HUVEC) were cultured in the presence of IFN-γ (100
IU/ml) for 4 days to mimic inflammation. Expression of various genes that are known to be induced by IFN-γ is shown (GBP2, IFITM1),
including genes that are involved in HLA processing and presentation (TAP1, CD74, PSMB9 andHLA-DRA). Circles represent samples
cultured without IFN-γ, while squares indicate samples after IFN-γ treatment. Red symbols indicate samples which have been excluded from
the dataset for incomplete maturation.
doi:10.1371/journal.pone.0155165.g001
Gene Expression to Analyze Immunotherapeutic Candidates
PLOS ONE | DOI:10.1371/journal.pone.0155165 May 12, 2016 8 / 20
Table 1. Characteristics of leukemic cells selected for microarray gene expression analysis.
Samplea Originb WHO classiﬁcationc Other genetic abnormalitiesd
AML 2467 (CD33/
CD14)
PB Acute myeloid leukemia with inv(16)(p13.1q22); CBFB-MYH11 trisomy 8, trisomy 14, trisomy 21
AML 1310 (CD33/
CD14)
PB Acute myeloid leukemia with inv(16)(p13.1q22); CBFB-MYH11 -
AML 3097 (CD33) BM Acute promyelocytic leukemia with t(15;17)(q22;q12);
PML-RARA
CEBPA polymorphism (6bp insertion)e
AML 2179 (CD33) PB Acute promyelocytic leukemia with t(15;17)(q22;q12);
PML-RARA
-
AML 1591 (CD33) PB Acute promyelocytic leukemia with t(15;17)(q22;q12);
PML-RARA
FLT3-ITD positive
AML 1466 (CD33/
CD14)
BM Acute myeloid leukemia with t(9;11) (p22q23); MLLT3-MLL -
AML 4781 (CD33/
CD14)
PB Acute myeloid leukemia with inv(3)(q21q26.2); RPN1-EVI1 EVI1 overexpression, monosomy 7, del (7) (q21), add
(12) (p11); complexf
AML 587 (CD33) BM Acute myeloid leukemia with mutated NPM1 FLT3-ITD positive
AML 2536 (CD33) BM Acute myeloid leukemia with mutated NPM1 -
AML 4443 (CD33) PB Acute myeloid leukemia with mutated NPM1 FLT3-ITD positive
AML 6395 (CD33) PB Acute myeloid leukemia with mutated NPM1 -
AML 3370 (CD33) PB Acute myeloid leukemia with mutated NPM1 -
AML 5205 (CD33/
CD14)
PB Acute myeloid leukemia with mutated NPM1 FLT3-ITD positive
AML 3590 (CD33) PB t-AML -
AML 3714 (CD33) BM AML-NOS, with minimal differentiation complexf
AML 5596 (CD33) BM AML-NOS, without maturation -
AML 3778 (CD33) PB AML-NOS, without maturation complexf
AML 3870 (CD33) BM AML-NOS, with maturation trisomy 8
AML 6283 (CD33) BM AML-NOS, with maturation FLT3-ITD positive
AML 1143 (CD33) PB AML-NOS, acute monoblastic leukemia -
AML 3009 (CD33) BM AML-NOS, acute monoblastic leukemia FLT3-ITD positive
AML 5074 (CD33/
CD14)
PB AML-NOS, acute monoblastic leukemia complexf
Sample origin WHO classiﬁcation other genetic abnormalities
ALL 2391 (CD19) BM B Lymphoblastic leukemia NOS trisomy 5
ALL 2872 (CD19) BM B Lymphoblastic leukemia NOS -
ALL 1299 (CD19) BM B Lymphoblastic leukemia NOS del(6) (q21q23), del(Y)
ALL 3281 (CD19) PB B Lymphoblastic leukemia NOS -
ALL 5903 (CD19) BM B Lymphoblastic leukemia with t(9;22)(q34;q11.2); BCR-ABL1
p190
complexf
ALL 3639 (CD19) BM B Lymphoblastic leukemia with t(9;22)(q34;q11.2); BCR-ABL1
p190
trisomy 5, trisomy 8
ALL 2375 (CD19) BM B Lymphoblastic leukemia with t(4;11) (q21;q23); MLL
rearranged
-
ALL 1833 (CD19) PB B Lymphoblastic leukemia with t(11;19) (q23;p13.3); MLL
rearranged
-
ALL 3655 (CD19) BM B Lymphoblastic leukemia with hyperdiploidy complexf
Sample origin WHO classiﬁcation Other genetic abnormalities
CML 3471
(CD34)g
BM Chronic myelogenous leukemia, BCR-ABL1 positive del (9q); complexf
CML 5036
(CD34)h
PB Chronic myelogenous leukemia, BCR-ABL1 positive t(2;9;22) (p13;q34;q11)
(Continued)
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The effect of inflammation on gene expression in non-hematopoietic cell
types
To evaluate gene expression in non-hematopoietic cell types under inflammatory conditions,
we performed microarray gene expression analysis on fibroblasts, keratinocytes, PTEC,
Table 1. (Continued)
CML 3087
(CD34)h
BM Chronic myelogenous leukemia, BCR-ABL1 positive del (Xp), del (17q); complexf
CML 4779
(CD34)h
BM Chronic myelogenous leukemia, BCR-ABL1 positive -
CML 1303
(CD34)h
BM Chronic myelogenous leukemia, BCR-ABL1 positive -
Sample origin WHO classiﬁcation Genetic abnormalitiesi
Trisomy 12 13q14.3 ATM p53
CLL 1695 (CD19/
CD5)
BM Chronic lymphocytic leukemia absent del/delj del normal
CLL 4725 (CD19/
CD5)f
BM Chronic lymphocytic leukemia absent del normal del
CLL 5535 (CD19/
CD5)
PB Chronic lymphocytic leukemia absent del normal normal
CLL 6242 (CD19/
CD5)
PB Chronic lymphocytic leukemia absent normal normal del
CLL 2159 (CD19/
CD5)
PB Chronic lymphocytic leukemia absent del/delj normal normal
Sample origin WHO
classiﬁcation
Genetic abnormalitiesi
Hyperdiploidy numeric
abnorm
chr1 13q14 p53 IgH
rearrangements
t(14;16) (q32;
q23)
MM 5987 (CD38)f BM Plasma cell
myeloma
hyperdiploid +9, +15 +1q del normal t(4;14)(p16;q32) absent
MM 5744 (CD38)f BM Plasma cell
myeloma
diploid absent +1q del normal t(4;14)(p16;q32) absent
MM 6622 (CD38) BM Plasma cell
myeloma
diploid absent normal normal normal normal absent
MM 4298 (CD38) BM Plasma cell
myeloma
diploid -15 normal del del t(4;14)(p16;q32) absent
MM 5019 (CD38)f BM Plasma cell
myeloma
diploid absent normal del normal t(11;14)(q13;q32) absent
a Markers for ﬂow cytometric isolation of malignant cells are indicated between brackets. AML cells have been isolated by expression of CD33 (CD33) or a
combination of CD33 and CD14 (CD33/CD14) in which CD33 expressing AML cells positive or negative for monocyte lineage differentiation marker CD14
have been selected as two separate cell populations. CLL cells have been selected for co-expression of CD19 and CD5. ALL, CML and MM cells have
been isolated by expression of CD19, CD34 and CD38, respectively.
b Origin of sample either peripheral blood (PB) or bone marrow (BM) mononuclear cells.
c WHO classiﬁcation as described by Swerdlow et al, 2008.
d Other abnormalities include numerical abnormalities, CEBPA mutations, FLT3-ITD, or EVI1 overexpression.
e Partial del(6q?) in fraction of the cells.
f Complex karyotypes are depicted in S1 Table.
g CML in blast crisis.
h CML in chronic phase.
i Genetic abnormalities as detected by FISH for CLL or MM.
j del/del; homozygous deletion.
doi:10.1371/journal.pone.0155165.t001
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melanocytes and HUVEC cultured in the presence of IFN-γ and compared probe fluorescence
with the same samples that were cultured in the absence of cytokines. In total, 9 probes were
>10-fold induced by IFN-γ in all 5 non-hematopoietic cell types. These probes were specific for
interferon-inducible genes (GBP2) as well as genes involved in HLA-class II processing and pre-
sentation (CD74,HLA-DMA,HLA-DPA1,HLA-DRA,HLA-DRB4 and LOC649143). In addi-
tion, 106 probes were> 10-fold up-regulated in at least one non-hematopoietic cell type (Fig 2
and S4 Table). Up-regulated gene expression by IFN-γ was detected for 32, 83, 35, 11 and 40
probes in fibroblasts, keratinocytes, PTEC, melanocytes and HUVEC, respectively, while expres-
sion levels in the absence of IFN-γ were similar between these non-hematopoietic cell types.
To determine whether gene expression patterns are different between cell types cultured
with a cocktail of inflammatory cytokines as compared to IFN-γ alone, we performed
Table 2. R2 values for regression analysis betweenmicroarray and q-PCRa.
Geneb Probe 1c Probe 2c Maximum expression in datasetd R2
Probe 1 Probe 2 Probe averagee
HLA-DRA ILMN_1689655 ILMN_2157441 15.03 14.61 14.82 0.925f
TAP1 ILMN_1751079 14.78 0.759
COL1A1 ILMN_1701308 14.75 0.948
CD14 ILMN_1740015 ILMN_2396444 13.20 14.80 14.00 0.732
ELANE ILMN_1706635 13.87 0.783
CD34 ILMN_1732799 ILMN_2341229 13.59 13.54 13.57 0.944
CD19 ILMN_1782704 13.49 0.985
PRTN3 ILMN_1753584 13.16 0.867
CD33 ILMN_1747622 11.66 0.834
KRT8 ILMN_1753584 11.55 0.974
P2RX5 ILMN_1677793 11.09 0.679
MOB3A ILMN_1721344 10.88 0.326
POLE ILMN_1728199 10.76 0.409
C19orf48 ILMN_1759184 ILMN_2383484 11.34 10.11 10.73 0.266
HMHA1 ILMN_1811392 10.11 0.779
CLYBL ILMN_1663538 9.30 0.487
ROR1 ILMN_1655904 9.20 0.938
COIL ILMN_1688034 8.65 -0.001
MS4A1g ILMN_1776939 8.62 0.320
PFAS ILMN_1755862 8.61 0.216
PTPRCh ILMN_2340217 ILMN_1653652 8.07 8.78 8.43 0.347
APOBEC3B ILMN_2219466 8.23 0.652
TTK ILMN_1788166 8.09 0.545
WT1 ILMN_1802174 8.00 0.856
a R2 values for individual genes were calculated from the regression model.
b Ofﬁcial gene symbols are depicted for genes as included in the q-PCR validation set.
c Illumina probe IDs as measured in the microarray database.
d Maximum probe ﬂuorescence as measured by microarray gene expression analysis in the sample set for q-PCR validation.
e Average of maximum probe ﬂuorescence is given for genes with more than 1 probe.
f R2 >0.667 are bold.
g MS4A1 is also known as CD20.
h PTPRC is also known as CD45.
doi:10.1371/journal.pone.0155165.t002
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microarray gene expression analysis on fibroblast samples that we cultured in the presence of
culture supernatant from an activated CD4 T-cell clone in which high levels of IFN-γ, IL-13,
TNF-α and IL-2 were detected. Table 3 shows all separate probes (n = 47) for genes that are
>10-fold up-regulated by IFN-γ or T-cell supernatant. The data show that 46 out of 47 probes
were at least 5-fold up-regulated under both conditions, indicating that IFN-γ can be used as
single agent to induce an inflammatory gene expression signature.
Gene expression profiles of immunotherapeutic targets for
hematological malignancies
Minor histocompatibility antigens with hematopoiesis-restricted expression are relevant tar-
gets to selectively induce anti-tumor reactivity after alloSCT. Only a limited number of minor
histocompatibility antigens have been reported to be hematopoiesis-restricted. To evaluate
expression of these antigens in our microarray dataset of malignant and healthy hematopoietic
and non-hematopoietic cell types, we generated gene expression profiles for the known thera-
peutic minor histocompatibility antigens HA-1 (HMHA1) [33, 34], LB-ARHGDIB-1R
Fig 2. Effect of IFN-γ on gene expression in non-hematopoietic cell types.Microarray gene expression analysis was performed on
fibroblasts, keratinocytes, PTEC, melanocytes and HUVEC cultured in the presence of IFN-γ and probe fluorescence was compared with
the same cell samples cultured in the absence of IFN-γ. All probes that were >10-fold up-regulated after IFN-γ treatment in one or more cell
types are depicted. Probe fluorescence is shown on the y-axis in logarithmic scale. Circles show gene expression in the absence of IFN-γ,
while squares indicate expression in the presence of IFN-γ. For each cell type, the number of probes that are >10-fold up-regulated by IFN-
γ is shown.
doi:10.1371/journal.pone.0155165.g002
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Table 3. Gene expression in skin fibroblasts as induced by IFN-γ and T-cell supernatant.
Probe IDa Geneb Fibroblasts Fibroblasts + IFN-γ Fold Increased Fibroblasts Fibroblasts + T-
supe
Fold Increase
AVGc SDc AVG SD AVG SD AVG SD
ILMN_1705247 ACSL5 71,48 18,18 915,69 4,61 12,81 57,07 5,64 410,79 21,92 7,20
ILMN_1756862 APOL3 127,45 50,12 1744,54 88,76 13,69 126,02 3,27 1215,58 198,99 9,65
ILMN_1720048 CCL2 405,52 320,65 566,98 379,69 1,40 146,88 58,76 3739,10 578,67 25,46
ILMN_2098126 CCL5 56,56 5,03 87,02 7,13 1,54 80,04 4,21 1448,07 17,78 18,09
ILMN_1773352 CCL5 55,04 4,49 70,60 14,72 1,28 52,54 0,90 564,89 13,32 10,75
ILMN_1772964 CCL8 79,79 26,74 654,98 396,22 8,21 76,86 23,08 1092,76 27,37 14,22
ILMN_1736567 CD74 105,73 53,25 4540,97 791,32 42,95 59,62 4,58 6697,04 438,61 112,33
ILMN_2379644 CD74 77,73 31,38 1627,96 282,95 20,94 46,04 4,27 3008,86 137,93 65,35
ILMN_1761464 CD74 51,45 1,29 730,79 41,60 14,20 45,18 2,03 518,30 79,50 11,47
ILMN_2047511 CENTA1 187,61 62,18 1916,52 1491,98 10,22 94,46 27,37 664,84 489,58 7,04
ILMN_1791759 CXCL10 51,04 4,63 178,24 64,32 3,49 54,72 1,54 1600,24 844,80 29,24
ILMN_1745356 CXCL9 48,55 4,44 303,32 131,99 6,25 41,91 1,69 5149,88 3359,40 122,89
ILMN_2388547 EPSTI1 124,13 41,46 1691,41 606,22 13,63 165,03 48,22 2084,78 643,31 12,63
ILMN_1701114 GBP1 183,62 52,59 2569,15 182,46 13,99 182,31 43,53 3793,63 414,77 20,81
ILMN_2148785 GBP1 143,83 37,33 1191,59 6,56 8,28 274,42 56,92 5802,20 1534,56 21,14
ILMN_1774077 GBP2 745,66 345,68 17626,86 2385,66 23,64 582,62 90,58 7100,17 300,24 12,19
ILMN_1771385 GBP4 48,49 2,67 903,78 21,36 18,64 57,47 0,85 1439,61 406,66 25,05
ILMN_2114568 GBP5 56,21 4,33 1124,80 148,70 20,01 48,52 1,19 1189,30 25,32 24,51
ILMN_1803945 HCP5 91,78 15,97 892,47 51,92 9,72 71,62 1,81 936,66 97,71 13,08
ILMN_1778401 HLA-B 1305,90 484,58 9930,80 649,29 7,60 1354,92 495,95 15916,89 2069,86 11,75
ILMN_1695311 HLA-DMA 542,10 87,50 7641,55 2580,39 14,10 355,31 31,05 3309,74 1393,47 9,32
ILMN_1761733 HLA-DMB 89,92 32,72 2127,14 1065,96 23,66 66,70 10,93 930,50 471,41 13,95
ILMN_1659075 HLA-DOA 51,01 4,51 897,08 186,07 17,59 51,14 1,29 312,10 118,38 6,10
ILMN_1772218 HLA-DPA1 160,29 7,45 3916,33 585,53 24,43 119,74 3,57 2708,72 724,98 22,62
ILMN_1808405 HLA-DQA1 59,19 9,86 887,82 661,25 15,00 41,27 0,96 870,79 606,77 21,10
ILMN_1689655 HLA-DRA 176,76 126,36 12566,25 3920,68 71,09 93,09 0,69 4449,93 1823,37 47,80
ILMN_2157441 HLA-DRA 138,34 86,70 5530,45 687,54 39,98 62,36 1,05 5817,44 2067,78 93,29
ILMN_1715169 HLA-DRB1 49,64 3,33 302,36 253,61 6,09 51,16 0,40 880,52 833,29 17,21
ILMN_1752592 HLA-DRB4 97,08 25,57 3135,67 1486,29 32,30 59,02 1,21 2467,91 384,34 41,81
ILMN_1697499 HLA-DRB5 73,82 26,82 826,23 777,15 11,19 48,12 0,54 1122,44 1073,92 23,32
ILMN_2066060 HLA-DRB6 56,77 0,82 317,56 109,15 5,59 60,67 1,64 812,22 438,83 13,39
ILMN_2066066 HLA-DRB6 52,33 1,69 192,74 48,32 3,68 48,40 2,49 988,46 215,83 20,42
ILMN_1723912 IFI44L 63,42 5,51 1192,97 174,91 18,81 64,62 10,67 1230,95 168,61 19,05
ILMN_2347798 IFI6 212,00 45,36 2234,49 782,87 10,54 664,54 215,55 12733,61 8737,71 19,16
ILMN_1739428 IFIT2 148,34 6,69 2190,73 666,22 14,77 333,39 47,93 2205,74 1097,87 6,62
ILMN_1701789 IFIT3 309,27 24,42 5293,10 106,34 17,11 248,64 35,15 2465,82 954,09 9,92
ILMN_1664543 IFIT3 61,94 6,84 500,90 52,90 8,09 111,53 4,69 1162,56 556,31 10,42
ILMN_2334296 IL18BP 124,90 13,66 3132,98 608,04 25,08 68,50 2,03 2266,51 1379,17 33,09
ILMN_2368530 IL32 54,42 6,19 149,61 4,61 2,75 109,67 4,68 1873,74 978,51 17,09
ILMN_1656310 INDO 48,99 9,14 523,11 154,06 10,68 45,64 0,65 5685,52 4062,65 124,58
ILMN_1708375 IRF1 498,42 212,95 2664,97 295,19 5,35 277,69 29,54 4185,18 822,05 15,07
ILMN_1662358 MX1 198,75 6,86 10822,34 4316,73 54,45 671,64 353,82 6055,89 2475,95 9,02
ILMN_1701613 RARRES3 291,17 134,16 9431,88 2494,20 32,39 190,98 15,69 4008,61 1773,14 20,99
ILMN_1751079 TAP1 1184,40 16,21 13220,08 1203,62 11,16 824,61 168,64 6181,11 527,53 7,50
(Continued)
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(ARHGDIB) [35, 36] and LB-ITGB2-1 (ITGB2) [37]. Fig 3A shows that maximum probe fluo-
rescence was< log 11 for HMHA1, while values> log 11 were measured for ARHGDIB and
ITGB2. Despite low probe fluorescence, HMHA1 was accurately measured by microarray gene
expression analysis as illustrated by strong association with q-PCR data (Table 2; R2 = 0.779).
The data also show that expression ofHMHA1 and ARHGDIB was restricted or predominant
in all or the majority of hematopoietic cells, while expression of ITGB2 was specific for certain
hematopoietic lineages. No expression of HMHA1 could be measured in any of the non-
hematopoietic cell types even when cultured with IFN-γ, while ARHGDIB and ITGB2 showed
intermediate and low expression in HUVEC and fibroblasts, respectively. In conclusion, micro-
array analysis confirmed restricted or predominant gene expression in hematopoietic cells for
therapeutic minor histocompatibility antigens.
In addition to minor histocompatibility antigens, surface antigens with restricted expression
on hematopoietic lineages or malignancies are relevant targets for therapeutic antibodies or
CAR T-cell therapy. We therefore explored our microarray dataset to evaluate gene expression
for surface antigens with known expression on B cells (CD19 and CD79B) or B-cell malignan-
cies (ROR1). Fig 3B shows that maximum probe fluorescence was> log 11 for CD19 and
CD79B, while values< log 11 were observed for ROR1. Despite low probe fluorescence, ROR1
microarray data were reliable as confirmed by q-PCR data (R2 = 0.938, Table 2). Furthermore,
the data show that CD19 was highly expressed in healthy B cells, ALL and CLL, while no
expression was detected in any other (non-)hematopoietic cell type. ROR1 demonstrated over-
expression in CLL, while expression of this gene was not detectable in healthy B cells. However,
ROR1 expression was also found in biliary epithelial cells and to variable extents in skin fibro-
blasts. Finally, expression of CD79B was most pronounced in the B-cell lineage, but expression
was also found in a variety of other (non-)hematopoietic cell types. Thus, restricted or predom-
inant expression in (malignant) B cells could be confirmed by microarray gene expression anal-
ysis for surface antigens with known B-cell specific expression.
In conclusion, the data show that our microarray gene expression dataset as collected for
(malignant) hematopoietic cell samples and non-hematopoietic cell types cultured under
steady state and inflammatory conditions provides a high-throughput platform for detailed
analysis and selection of candidate targets with hematopoiesis (lineage)-restricted expression
for immunotherapy of hematological malignancies.
Table 3. (Continued)
Probe IDa Geneb Fibroblasts Fibroblasts + IFN-γ Fold Increased Fibroblasts Fibroblasts + T-
supe
Fold Increase
AVGc SDc AVG SD AVG SD AVG SD
ILMN_1678841 UBD 49,97 2,18 76,70 15,87 1,53 52,95 1,42 1077,09 664,73 20,34
ILMN_1727271 WARS 1219,84 167,93 18566,63 8233,61 15,22 364,88 11,13 7669,97 593,84 21,02
ILMN_2337655 WARS 1267,64 209,92 13887,52 4384,17 10,96 508,79 30,61 11333,68 2227,47 22,28
a Illumina probe IDs as included in the microarray database.
b Ofﬁcial gene symbols are depicted for genes that are >10-fold up-regulated by IFN-γ, T-cell supernatant or both.
c AVG and SD are the average and standard deviation of probe ﬂuorescence as measured in different ﬁbroblast samples, respectively.
d Fold increase was calculated from the average probe ﬂuorescence as measured in ﬁbroblasts after pre-treatment with IFN-γ or T-cell supernatant
divided by the average probe ﬂuorescence in the corresponding ﬁbroblast samples cultured without cytokines. Values in bold indicate >10-fold
upregulated gene expression by IFN-γ, T-cell supernatant or both.
e T-sup; T-cell supernatant harvested from an activated CD4 T-cell clone containing high levels of inﬂammatory cytokines.
doi:10.1371/journal.pone.0155165.t003
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Fig 3. Gene expression profiles for potential targets for immunotherapy of hematological malignancies.Gene expression profiles were
generated for hematopoiesis-restricted minor histocompatibility antigens and B-cell specific surface antigens as potential targets for
immunotherapy of hematological malignancies. (A) Gene expression profiles for minor histocompatibility antigens HA-1 (HMHA1),
LB-ARHGDIB-1R (ARHGDIB) and LB-ITGB2-1 (ITGB2). (B) Gene expression profiles for B-cell specific antigensCD19, CD79B and ROR1.
Probe fluorescence intensity is shown on the x-axis in logarithmic scale. On the y-axis malignant and healthy (non-)hematopoietic cell types as
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Discussion
In this study, we performed microarray gene expression analysis on malignant and healthy
hematopoietic cells and various non-hematopoietic cell types cultured under steady state and
inflammatory conditions. Quality control was performed to confirm cell-type origin of the
samples and to exclude peripheral blood contamination of non-hematopoietic samples. Valida-
tion of gene expression was performed by quantitative RT-PCR and an inflammatory gene sig-
nature was established by comparing gene expression between different non-hematopoietic
cells after pre-treatment with IFN-γ. Furthermore, we demonstrated the value of the microar-
ray dataset to generate gene expression profiles for potential targets for immunotherapy of
hematological malignancies.
Validation of the Illumina HT12 microarray gene expression dataset by q-PCR analysis
demonstrated a strong correlation between both platforms with an overall corrected R2 of
0.868. However, maximum probe fluorescence as measured in any cell type of the dataset var-
ied significantly. No or low fluorescence can be the consequence of poor probe quality or
absence or low expression of the gene transcript in the dataset, while high probe fluorescence
indicates that the gene transcript is strongly expressed. Strong correlation between q-PCR and
microarray data with R2> 0.667 was obtained for all probes with maximum
fluorescence > log 11. Of the 28,280 probes (20,215 when selecting probes for unique genes)
for designated NM transcripts on Illumina HT12 chips, fluorescence > log 11 was measured
for 4301 probes (15%), 3787 (19%) after selection of probes for unique genes. Provided that
~50% of all genes as present in the human genome are expressed in differentiated cell types
[38], expression profiles can be determined with high accuracy for ~40% of genes. For probes
with maximum fluorescence< log 11, qualitative analysis can still be performed, but q-PCR
studies are recommended for quantitative gene expression analysis.
To evaluate up-regulated gene expression under inflammatory conditions, we cultured vari-
ous non-hematopoietic cell types in the presence of IFN-γ and compared gene expression to
the same cells cultured in the absence of cytokines. In total 106 probes were>10-fold up-regu-
lated in at least one non-hematopoietic cell type with melanocytes being less sensitive to IFN-γ
pre-treatment (n = 11 probes) than keratinocytes (n = 83 probes). To determine whether IFN-
γ can be used as single agent to mimic inflammation, we also cultured fibroblasts in the pres-
ence of T-cell culture supernatant containing high levels of inflammatory cytokines (IFN-γ, IL-
13, TNF-α and IL-2). There was great overlap between genes up-regulated by IFN-γ and T-cell
culture supernatant, illustrating that IFN-γ as single compound can create an inflammatory
gene signature. As such, gene expression analysis of samples cultured with IFN-γ can be used
to estimate toxicity of immunotherapeutic targets against non-hematopoietic cells under
inflammatory conditions.
In our microarray dataset, contamination of non-hematopoietic cells with peripheral blood
cells was excluded to allow identification and selection of genes with hematopoietic (lineage)-
restricted expression, which may encode relevant targets for immunotherapy of hematological
malignancies. To evaluate the value of our microarray dataset to analyze and select potential
targets for immunotherapy of hematological malignancies, we generated gene expression pro-
files for hematopoiesis-restricted minor histocompatibility antigens that are recognized by spe-
cific T cells in the context of HLA. Microarray analysis confirmed restricted or predominant
expression of these antigens in hematopoietic cells, but ARHGDIB and ITGB2 also showed
included in the microarray dataset are shown. Each dot represents a different sample and the mean and standard deviation of gene expression
is shown for each cell type.
doi:10.1371/journal.pone.0155165.g003
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intermediate and low expression in endothelial cells and fibroblasts, respectively. Since actual
antigen presentation by HLA is not measured by microarray gene expression analysis, addi-
tional experiments are required to further evaluate potential toxicity against non-hematopoi-
etic cell types with detectable expression of the gene of interest. For ARHGDIB and ITGB2, we
measured T-cell reactivity against endothelial cells and fibroblasts, but did not find any evi-
dence for toxicity [35, 37]. In addition to minor histocompatibility antigens, we generated gene
expression profiles for surface antigens with known B-cell specific expression that can be tar-
geted independent of HLA by CAR-based immunotherapy. Microarray analysis confirmed
restricted or predominant expression of these antigens in (malignant) B cells. However, CD79B
was also expressed in a variety of other (non-)hematopoietic cell types, which was supported
by Jahn et al. [39], who demonstrated that intracellular CD79B peptides are presented by HLA
and recognized by specific T cells on other cell types than B cells. Since actual surface expres-
sion is not measured by microarray gene expression analysis, additional experiments are
required to evaluate whether CD79B is an appropriate target for CAR-based therapy. For
ROR1, microarray data confirmed overexpression in CLL as compared to healthy B cells, sup-
porting its relevance as therapeutic target. ROR1 expression was also found in biliary epithelial
cells and to variable extents in skin fibroblasts, but no evidence has been found that gene
expression in these cell types leads to detectable surface expression as illustrated by the safety
of CAR-based therapy targeting ROR1 in nonhuman primates [40, 41].
In summary, we performed microarray gene expression analysis on hematological malig-
nancies of different origins, healthy hematopoietic cells and various (IFN-γ pre-treated) non-
hematopoietic cell types and demonstrate that our microarray gene expression database allows
detailed analysis and selection of candidate targets with hematopoietic (lineage-)restricted
expression for immunotherapy of hematological cancers.
Supporting Information
S1 Fig. Validation of the cell type origin of non-hematopoietic samples. Gene expression for
cell type-specific genes as determined by microarray gene expression is shown. PTEC-specific
expression is shown for PAX8, KCNIP1, KCNJ16 and FXYD2; HUVEC-specific expression is
shown for VWF, CDH5, ESM1 and CLEC14A; small intestine-specific expression is shown for
OLFM4, RBP2, FABP6 and FAM3B. Gut-associated expression as defined by detectable expres-
sion in gut (both colon and small intestine) as well as a limited number of other non-hemato-
poietic cell types is shown for TFF3, LGALS4, CDH17 and TACSTD1 and lung-associated
expression is demonstrated for PLUNC, SCGB3A1, SLPI andMSMB. Probe fluorescence as
measured by microarray gene expression analysis is indicated on the x-axis in logarithmic
scale.
(PDF)
S2 Fig. Clustering analysis of hematopoietic and non-hematopoietic cell types.Hierarchical
clustering analysis was performed on all healthy hematopoietic and non-hematopoietic cell
types as included in the dataset based on microarray expression profiling of all genes. Hemato-
poietic cell types were accurately distinguished from non-hematopoietic cell types.
(PDF)
S3 Fig. Gene expression for differentiation markers on cell populations isolated from
malignant hematopoietic samples. Gene expression for differentiation markers on cell popu-
lations isolated from AML, CML, ALL, CLL and MM samples is shown. Black symbols indicate
gene expression for surface markers that were used for isolation of malignant cell populations,
while grey symbols indicate gene expression for other differentiation markers on isolated cell
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populations. From AML samples, cell populations were isolated by surface expression of CD33
only (filled circles) or by CD33 in combination with CD14 (open triangles and open squares
represent CD33 positive cell populations that are positive or negative for CD14, respectively).
Probe fluorescence is indicated on the x-axis in logarithmic scale.
(PDF)
S4 Fig. Correlation plots for q-PCR and microarray data. Plots depicting regression models
are given for each gene separately. q-PCR values are given on the x-axis and microarray probe
fluorescence on the y-axis. For the purpose of graphical representation Cp values were normal-
ized according to reference genes prior to fitting the regression model. Individual R2 values
derived from the model are depicted in the left upper corner of each plot. Genes are shown in
order of maximum probe fluorescence as measured in any cell type of the dataset as selected
for q-PCR validation starting with genes with highest maximum probe fluorescence. Each dot
represents the mean corrected q-PCR value of duplicate measurements and the probe fluores-
cence intensity as measured by microarray gene expression analysis. Q-PCR measurements
were corrected for expression of reference genes (HMBS, ACTB and GAPDH) in the corre-
sponding sample.
(PDF)
S1 Methods. Supplemental methods.
(PDF)
S1 Table. Complex karyotypes of leukemic cells selected for microarray gene expression
analysis.
(PDF)
S2 Table. Assays and probe IDs for genes included for validation by q-PCR.
(PDF)
S3 Table. RNA samples used for validation by q-PCR.
(PDF)
S4 Table. Effect of IFN-γ on gene expression in non-hematopoietic cell types.
(PDF)
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